Enlivex Therapeutics Ltd [NASDAQ: ENLV] stock went on an upward path that rose over 20.37% on Tuesday, amounting to a one-week price increase of more than 21.50%.
Over the last 12 months, ENLV stock dropped by -27.78%. The one-year Enlivex Therapeutics Ltd stock forecast points to a potential upside of 86.32. The average equity rating for ENLV stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $27.83 million, with 21.99 million shares outstanding and 18.76 million shares in the current float. Compared to the average trading volume of 155.14K shares, ENLV stock reached a trading volume of 4482533 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Enlivex Therapeutics Ltd [ENLV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ENLV shares is $9.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ENLV stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Enlivex Therapeutics Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 02, 2021.
The Average True Range (ATR) for Enlivex Therapeutics Ltd is set at 0.12 The Price to Book ratio for the last quarter was 1.08, with the Price to Cash per share for the same quarter was set at 1.15.
ENLV Stock Performance Analysis:
Enlivex Therapeutics Ltd [ENLV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.50. With this latest performance, ENLV shares dropped by -4.41% in over the last four-week period, additionally sinking by -3.70% over the last 6 months – not to mention a drop of -27.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENLV stock in for the last two-week period is set at 57.25, with the RSI for the last a single of trading hit 64.73, and the three-weeks RSI is set at 53.13 for Enlivex Therapeutics Ltd [ENLV]. The present Moving Average for the last 50 days of trading for this stock 1.3537, while it was recorded at 1.1460 for the last single week of trading, and 1.7954 for the last 200 days.
Insight into Enlivex Therapeutics Ltd Fundamentals:
Enlivex Therapeutics Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.71 and a Current Ratio set at 9.71.
Enlivex Therapeutics Ltd [ENLV] Institutonal Ownership Details
The top three institutional holders of ENLV stocks are: ARMISTICE CAPITAL, LLC with ownership of 1.7 million shares, which is approximately 9.0808%. MORGAN STANLEY, holding 0.24 million shares of the stock with an approximate value of $$0.35 million in ENLV stocks shares; and MORGAN STANLEY, currently with $$0.1 million in ENLV stock with ownership which is approximately 0.3828%.
